Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
![AI](https://streamlined.nyc3.cdn.digitaloceanspaces.com/assets/ai-default.gif)
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Laboratory Corporation of America Holdings
Laboratory Corporation of America Holdings News
Laboratory Corporation of America Holdings Quantitative Score
![Website screenshot](https://streamlined.nyc3.cdn.digitaloceanspaces.com/website-screenshots/labcorp-com.webp)
About Laboratory Corporation of America Holdings
Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
Laboratory Corporation of America Holdings Earnings & Revenue
Laboratory Corporation of America Holdings Financials
Table Compare
Compare LH metrics with: | |||
---|---|---|---|
Earnings & Growth | LH | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | LH | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | LH | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | LH | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Laboratory Corporation of America Holdings Income
Laboratory Corporation of America Holdings Balance Sheet
Laboratory Corporation of America Holdings Cash Flow
Laboratory Corporation of America Holdings Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Buy |
Return on Equity | Buy |
Return on Assets | Buy |
Debt/Equity Ratio | Sell |
Price/Earnings Ratio | Sell |
Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Laboratory Corporation of America Holdings Dividends
Yield (TTM) | Dividend (TTM) | |
---|---|---|
Infinity% | 2.8800 |
Payment Date | Dividend | Frequency |
---|---|---|
2024-09-13 | 0.72 | Quarterly |
2024-06-12 | 0.72 | Quarterly |
2024-06-12 | 0.72 | Quarterly |
2024-03-13 | 0.72 | Quarterly |
2023-12-12 | 0.72 | Quarterly |
Historical Market Cap
Shares Outstanding
Laboratory Corporation of America Holdings Executives
Name | Role |
---|---|
Mr. Adam H. Schechter | President, Chief Executive Officer & Chairman |
Mr. Glenn A. Eisenberg | Chief Financial Officer & Executive Vice President |
Mr. Mark S. Schroeder | Executive Vice President, President of Diagnostics Laboratories & Chief Operating Officer |
Ms. Anita Z. Graham | Executive Vice President & Chief Human Resources Officer |
Dr. Brian J. Caveney J.D., M.D., M.P.H. | EVice President, President of Early Development Research Laboratories and Chief Medical & Scientific Officer |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Mr. Adam H. Schechter | President, Chief Executive Officer & Chairman | Male | 1965 | 4.66M |
Mr. Glenn A. Eisenberg | Chief Financial Officer & Executive Vice President | Male | 1961 | 1.87M |
Mr. Mark S. Schroeder | Executive Vice President, President of Diagnostics Laboratories & Chief Operating Officer | Male | 1961 | 1.43M |
Ms. Anita Z. Graham | Executive Vice President & Chief Human Resources Officer | Female | 1971 | 1.35M |
Dr. Brian J. Caveney J.D., M.D., M.P.H. | EVice President, President of Early Development Research Laboratories and Chief Medical & Scientific Officer | 1974 | 1.3M |
Laboratory Corporation of America Holdings Insider Trades
Date | 19 Aug |
Name | van der Vaart Sandra D |
Role | EVP, Chief Legal Officer |
Transaction | Disposed |
Type | S-Sale |
Shares | 2000 |
Date | 15 Aug |
Name | EISENBERG GLENN A |
Role | Chief Financial Officer, EVP |
Transaction | Disposed |
Type | S-Sale |
Shares | 2979 |
Date | 15 Aug |
Name | EISENBERG GLENN A |
Role | Chief Financial Officer, EVP |
Transaction | Disposed |
Type | S-Sale |
Shares | 2950 |
Date | 15 Aug |
Name | EISENBERG GLENN A |
Role | Chief Financial Officer, EVP |
Transaction | Disposed |
Type | S-Sale |
Shares | 9071 |
Date | 7 Aug |
Name | ANDERSON KERRII B |
Role | Director |
Transaction | Disposed |
Type | S-Sale |
Shares | 414 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
19 Aug | van der Vaart Sandra D | EVP, Chief Legal Officer | Disposed | S-Sale | 2000 |
15 Aug | EISENBERG GLENN A | Chief Financial Officer, EVP | Disposed | S-Sale | 2979 |
15 Aug | EISENBERG GLENN A | Chief Financial Officer, EVP | Disposed | S-Sale | 2950 |
15 Aug | EISENBERG GLENN A | Chief Financial Officer, EVP | Disposed | S-Sale | 9071 |
7 Aug | ANDERSON KERRII B | Director | Disposed | S-Sale | 414 |